RxSight (NASDAQ:RXST – Get Free Report) and InspireMD (NYSE:NSPR – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.
Valuation & Earnings
This table compares RxSight and InspireMD”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| RxSight | $134.48 million | 1.63 | -$38.94 million | ($1.13) | -4.65 |
| InspireMD | $10.84 million | 3.30 | -$19.92 million | ($0.64) | -1.20 |
InspireMD has lower revenue, but higher earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and price targets for RxSight and InspireMD, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| RxSight | 3 | 7 | 2 | 0 | 1.92 |
| InspireMD | 0 | 0 | 3 | 0 | 3.00 |
RxSight currently has a consensus target price of $7.17, suggesting a potential upside of 36.48%. InspireMD has a consensus target price of $4.50, suggesting a potential upside of 485.18%. Given InspireMD’s stronger consensus rating and higher possible upside, analysts clearly believe InspireMD is more favorable than RxSight.
Institutional & Insider Ownership
78.8% of RxSight shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 10.1% of RxSight shares are owned by company insiders. Comparatively, 25.0% of InspireMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares RxSight and InspireMD’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| RxSight | -36.80% | -17.35% | -14.70% |
| InspireMD | -413.96% | -69.42% | -57.68% |
Volatility & Risk
RxSight has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
Summary
InspireMD beats RxSight on 8 of the 14 factors compared between the two stocks.
About RxSight
RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
About InspireMD
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.
